IL17A and breast cancer: For instance, in gastric cancer models, cytotoxic chemotherapy with ipirubicin and paclitaxel decrease MDSCs population as a consequence of anti-proliferative and pro-apoptotic effects in which the MAPK and NFκB signaling pathways are involved.152 Also, acute lymphocytic leukemia patients treated with chemotherapeutic molecules have less suppressor cells, which contributes to a better prognosis.153 Breast cancer patients expressing IL-17, and a STAT3 activated pathway, have less tumor-infiltrated MDSCs,154 raising possibilities to target IL-17 as a therapeutic alternative.